Parents of JMML patients are advised to discuss survival information with their child’s doctor. Keep in mind that outcome data can show how other children with JMML responded to treatment, but cannot predict how any one child will respond.
The treatment of JMML patients has not led to long-lasting remissions in most cases. However, there are individual factors that influence patient outcome. In general, the outlook for JMML patients is not as good as it is for patients with other childhood blood cancers; for example, acute leukemias, chronic myeloid leukemia and lymphoma.
The median survival of JMML patients is less than 2 years. It is important to note that these statistics may underestimate survival to a degree since the data may include outcomes for patients who did not receive treatment.
Many factors influence patient survival. Factors that may indicate a less favorable outcome include:
- Older than 2 years of age
- A low platelet count in the blood
- Elevated levels of hemoglobin F in the blood
A few children younger than 1 year old with Noonan syndrome and a PTPN11 gene mutation have experienced a spontaneous improvement of their JMML. The same improvement has occurred in some children with RAS gene mutations, as well.